🇺🇸 FDA
Pipeline program

11C-UCB-J, 18F-DPA-714, [11C]PiB

D23-P006

Phase 2 small_molecule active

Quick answer

11C-UCB-J, 18F-DPA-714, [11C]PiB for Alzeihmer disease is a Phase 2 program (small_molecule) at Pari Pharma GmbH with 1 ClinicalTrials.gov record(s).

Program details

Company
Pari Pharma GmbH
Indication
Alzeihmer disease
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials